Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia
Researchers are comparing AVE1625 and placebo to find out how the approaches affect memory, attention and other thinking skills in people with schizophrenia.
Understand this study
What is this study about?
Researchers are comparing AVE1625 and placebo to find out how the approaches affect memory, attention and other thinking skills in people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Bridgewater and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 873
- Sponsor
- Sanofi
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00439634
- Official title
Show the full official title
A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of 3 Oral Doses of AVE1625 and Placebo on Top of Either Olanzapine, Risperidone/Paliperidone, Quetiapine or Aripiprazole in the Treatment of Cognitive Impairment in Schizophrenia.
Recruitment & locations
Bridgewater, United States · Laval, Canada
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing AVE1625 and placebo to find out how the approaches affect memory, attention and other thinking skills in people with schizophrenia.
Who is behind this study?
The study sponsor is Sanofi.
Does this study involve medication?
Yes. The study involves medication, including AVE1625 and placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
